Novel biomarkers predicting cardiac function after acute myocardial infarction

    loading  Checking for direct PDF access through Ovid

Abstract

Background

Measurement of biomarkers provides a cost-effective and widely available method to estimate cardiac dysfunction and clinical outcome of patients with acute myocardial infarction (AMI).

Sources of data

PubMed entries with terms ‘myocardial infarction’ and the respective biomarker.

Areas of agreement

Cardiac troponins and natriuretic peptides are closely related to left ventricular dysfunction and the occurrence of adverse clinical events following AMI.

Areas of contention

The incremental value of novel biomarkers is controversial.

Future directions

The combination of traditional and novel biomarkers might further improve risk stratification of patients with AMI.

Search strategy

We searched all entries on the PubMed database with the MeSH terms ‘myocardial infarction’ and ‘cardiac troponins’, ‘natriuretic peptides’, ‘copeptin’, galectin-3’, ‘corin’, ‘fetuin-A’, ‘adiponectin’ and ‘microRNA’.

Related Topics

    loading  Loading Related Articles